Skip to content
06/16/2026
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Merlintrader Trading Pub

Merlintrader Trading Pub

Biotech catalyst news and analysis. FDA PDUFA tracker

DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Primary Menu
  • Merlintrader
    • About Merlintrader
    • Merlintrader Blog
    • Daily Briefing
    • Daily Watchlist
    • Discord
    • Latest News
    • Small & Medium Caps
    • CHARTSWATCHER 10% OFF !
    • Disclaimer
  • Cannabis Stocks Hub 2026
    • Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
    • Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
  • Space, Defense & AI Hub 2026
    • BlackSky Technology Inc. (NYSE: $BKSY) Stock Hub
    • BigBear.ai Holdings (NYSE: $BBAI)
    • Castellum, Inc. (NYSE American: $CTM) Stock Hub
    • Intuitive Machines (Nasdaq: $LUNR) Stock Hub
    • Ondas Holdings (NASDAQ: $ONDS) Stock Hub
    • Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub
    • Planet Labs PBC (NYSE: $PL)
    • POET Technologies (NASDAQ: $POET): Company Story,
    • Red Cat Holdings (NASDAQ: $RCAT)
    • Redwire Corporation (NYSE: $RDW) Stock Hub
    • Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub
    • Satellogic Inc. (Nasdaq: $SATL)
  • Biotech Stocks Hub
    • ADMA Biologics (Nasdaq: $ADMA)
    • Agios Pharmaceuticals (Nasdaq: $AGIO) Stock Hub
    • Alpha Tau Medical Ltd. (Nasdaq: $DRTS)
    • Altimmune Inc. (Nasdaq: $ALT )
    • Aquestive Therapeutics (Nasdaq: $AQST Stock Hub.
    • Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub
    • BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub
    • Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub
    • Corcept Therapeutics $CORT Stock Hub
    • CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub
    • Cytokinetics, Incorporated (Nasdaq: $CYTK)
    • Fate Therapeutics (Nasdaq: $FATE): Stock Hub
    • Geron Corporation (Nasdaq: $GERN) Stock Hub
    • ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub
    • Iovance Biotherapeutics (Nasdaq: $IOVA)
    • MannKind Corporation (Nasdaq: $MNKD) Stock Hub
    • Microbot Medical Inc. (Nasdaq: $MBOT) Stock Hub
    • Moleculin Biotech (Nasdaq: $MBRX) Stock Hub
    • Novavax, Inc. (Nasdaq: $NVAX) Stock Hub
    • NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub
    • Ocugen, Inc. (Nasdaq: $OCGN) Stock Hub
    • Ocular Therapeutix (Nasdaq: $OCUL) Stock Hub
    • Omeros Corporation (Nasdaq: $OMER): Stock Hub
    • Outlook Therapeutics (Nasdaq: $OTLK): Stock Hub
    • Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub
    • SeaStar Medical Holding Corporation (Nasdaq: $ICU) Stock Hub
    • SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub.
    • Summit Therapeutics (Nasdaq: $SMMT) Stock Hub
    • Travere Therapeutics (Nasdaq: $TVTX)
    • Viridian Therapeutics (Nasdaq: $VRDN)
  • FREE CATALYST CALENDAR
    • Catalyst Total Tracker
  • Merlintrader Travel Pub

Home - Medium Caps Trending - Asana Inc ( $ASAN ) Scaling SaaS & 2026 Growth Trajectory

  • Medium Caps Trending

Asana Inc ( $ASAN ) Scaling SaaS & 2026 Growth Trajectory

2 views
Asana Inc. (ASAN) – Work Management Platform & 2026 Growth Trajectory
NYSE: ASAN · SaaS · Work Management Platform

Asana Inc. (ASAN) – Scaling SaaS and 2026 Growth Trajectory

SaaS deep-dive report – focus on product platform, financial performance, customer metrics and growth scenarios around FY2026 results and the FY2027 outlook.
Report date: 4 March 2026 Financials updated through Q4 and full-year FY2026 (SEC filings) Educational use only – no investment recommendations
ASAN daily stock chart (Finviz)
ASAN – 1Y daily chart (Finviz) Click to open the interactive chart on Finviz (affiliate link).
Next earnings catalyst
Q1 FY2027 earnings (expected June 2026, quarter ending April 30, 2026) – focus on ARR, net retention and profitability trajectory after FY2026 inflection.
Key product milestone
Continued rollout of AI-assisted work management features and deeper enterprise adoption in 2026–2027; potential strategic partnerships or consolidation moves in the work management space.

Executive summary

Asana Inc. (NYSE: ASAN) is a leading cloud-based work management platform that helps teams organize, track and manage projects and tasks. Founded in 2008 by Dustin Moskovitz and Justin Rosenstein, the company went public in 2020 and has grown into a mid-cap SaaS player with a market capitalization of roughly 1.7–1.8 billion dollars as of early March 2026, based on a share price around 7.4 dollars and approximately 236–238 million shares outstanding.

In its most recent reported quarter, the fourth quarter of fiscal year 2026 (quarter ended January 31, 2026), Asana delivered 205.6 million dollars in revenue, up 9 percent year over year. For the full FY2026, revenues reached 790.8 million dollars, also up about 9 percent versus fiscal 2025. At the same time, the company generated 27.6 million dollars of operating cash flow in Q4 and approximately 90.4 million dollars for the full year, a very material improvement compared with the 14.9 million dollars of operating cash flow reported in FY2025. The free cash flow margin in Q4 was in the low double digits. [1]

Asana still reports a GAAP net loss, but the trajectory is clearly improving. Full-year FY2026 GAAP net loss narrowed to 189.0 million dollars from 255.5 million dollars in FY2025, while GAAP operating loss contracted from 266.7 to 197.3 million dollars over the same period. On an adjusted basis, the company has already moved into profitability, with positive non-GAAP operating income and positive non-GAAP net income for FY2026. [1] [2]

The business model is subscription-based SaaS: customers pay per seat, per month (or per year), and Asana tracks its progress primarily through Annual Recurring Revenue (ARR), net revenue retention (NRR) and the growth in higher-value “core customers”. Management recently highlighted that core customers spending 5,000 dollars or more on an annualized basis grew to 25,928, up 10 percent year over year, while overall net retention rates have normalized in the mid-90s percent range as customers optimize seat counts and budgets. [3]

This is a very different story from binary biotech catalysts. For Asana, the key drivers are steady SaaS scaling – customer acquisition, expansion within existing accounts, and operating leverage – combined with the path to sustainable profitability. The company competes against other work management and productivity platforms and must balance the trade-off between growth investments (especially in AI and enterprise features) and margin expansion.

Recent headwinds include softer software spending in some segments, pressure on net retention as customers consolidate tools, and intense competition from larger suites. On the other hand, Asana now has a more disciplined cost base, a clearer path to profitability and a growing base of higher-value enterprise and mid-market customers. The shift from “growth at any cost” to “profitable growth” is central to the FY2026/FY2027 narrative.

This report is strictly informational. It reviews Asana’s product platform, financial profile, customer metrics, competitive positioning and illustrative bull/bear scenarios for the next 12–24 months, without making any buy or sell recommendation on the stock.

Sources (section – Executive summary): Asana Inc. Form 10-K and 10-Q filings, FY2026 earnings press release and Form 8-K, plus selected institutional market data providers for share price, market capitalization and share count. [1] [2] [4]

Key stats (as of 3 March 2026 close)

Share price
$7.44
52-week range: $6.51 – $19.12
Moderate volatility for a mid-cap SaaS stock.
Market capitalization
≈ $1.7–1.8B
Implied by share price and diluted share count of roughly 236–238M.
Classified as a U.S. mid-cap SaaS company.
Analyst consensus
≈ $11
Average 12-month target around 10–12 dollars per share,
implying meaningful upside from current levels, with a neutral to moderate buy rating profile.
Q4 FY2026 revenue
$205.6M
Up 9% year over year, in line with recent SaaS slowdown but still positive.
Full-year FY2026 revenue: $790.8M, up about 9% versus FY2025.
Cash generation
$90.4M
FY2026 operating cash flow vs. $14.9M in FY2025.
Q4 FY2026 free cash flow margin in the low double digits.
Core customers
25,928
Customers spending at least $5,000 annually, up 10% year over year.
Overall NRR in the mid-90s percent range; core customer NRR slightly higher.
Sources (section – Key stats): FY2026 earnings release and 8-K, prior-year 10-K for FY2025 revenue and cash flow, and consolidated quote/consensus data from major institutional providers for price, market cap and analyst targets. [1] [2] [4]

Product platform and competitive positioning

Core work management capabilities

Asana’s platform is designed to centralize work across projects, portfolios and departments. The core idea is that teams should be able to see who is doing what, by when, with clear ownership and status tracking. Key functional pillars include:

  • Task and project management: creation, assignment and tracking of tasks with deadlines, dependencies, priorities and custom fields.
  • Views and workflows: list, board, timeline and calendar views, plus workflow automation to route work across teams.
  • Portfolio and resource management: visibility across multiple initiatives, capacity planning and cross-team coordination.
  • Reporting and dashboards: real-time dashboards on project status, workload and business metrics.
  • Integrations and API: connectors to common tools (email, chat, CRM, code repositories, BI) and an API for custom integrations.
  • AI-powered assistance: recently launched AI features that help generate task descriptions, summaries and recommendations.

Positioning in the work management landscape

The work management market is crowded, with several well-established and emerging competitors. A simplified comparison:

PlatformCompanyMarket focusTypical strengths vs. AsanaTypical weaknesses vs. Asana
Monday.comMonday.com Ltd.SMB to mid-marketHighly visual interface; strong marketing; rapid top-line growthLess depth for complex enterprise portfolio management
Microsoft 365 / ProjectMicrosoftEnterprise suitesBundled with existing licenses; ubiquitous presence in large organizationsLegacy UX in some modules; slower pace of innovation; heavier implementation
Jira / related toolsAtlassianSoftware and technical teamsDeep integration into development workflows; strong ecosystemSteeper learning curve; less intuitive for non-technical users
SmartsheetSmartsheet Inc.Enterprise PMO and operations teamsSpreadsheet-like model familiar to Excel users; robust governance toolsLess modern UX; often perceived as heavier to configure
AsanaAsana Inc.Mid-market to enterprise, knowledge-work teamsModern, intuitive UX; strong collaboration features; focus on work orchestration and AI assistanceNot the cheapest option; faces intense competition from bundled suites

Asana’s differentiation is strongest where organizations value user experience, cross-functional visibility and structured workflows more than raw feature count or lowest price. The company tries to sell not only a tool but a way of working, supported by customer success programs and best-practice templates.

Deep dive – AI assistance and automation

A significant part of Asana’s medium-term thesis rests on its ability to use artificial intelligence to remove friction in knowledge work. Examples of AI-supported use cases include:

  • Generating draft task descriptions and follow-up items from meeting notes or emails.
  • Summarizing project status across multiple tasks and assignees.
  • Highlighting risks (e.g. overdue critical tasks) and suggesting mitigation steps.
  • Recommending task assignments based on capacity and past workload patterns.

The strategic question is whether customers will be willing to pay for these capabilities at a premium compared with “good enough” functionality embedded in larger suites. AI is an opportunity, but it is also rapidly becoming table stakes across productivity tools, which means that execution, differentiation and integration depth will matter at least as much as the AI label itself.

Sources (section – Product platform and positioning): Asana product documentation, FY2026 and FY2025 filings and investor presentations describing the platform and go-to-market focus, plus independent industry research on work management and project portfolio tools. [2] [3]

Financial profile and path to profitability

Over the last two fiscal years Asana has shifted from a pure “growth” profile toward a more balanced “growth plus profitability” stance. The FY2026 numbers, compared with FY2025, illustrate this transition clearly.

Line item (USD millions)FY2025FY2026Key insight
Total revenue≈ $723.9M$790.8MAround 9% year-over-year growth, consistent with the company’s revised outlook.
GAAP operating loss$266.7M$197.3MOperating loss narrowed by roughly $70M as cost discipline improved.
GAAP net loss$255.5M$189.0MNet loss reduced by more than $60M year over year.
Operating cash flow$14.9M$90.4MCash generation improved materially; FY2026 operating cash flow is roughly 6x FY2025.
Q4 FCF marginLow single digitsLow double digitsFree cash flow margins inflected positively, supporting the profitability narrative.

Management’s FY2027 guidance focuses on maintaining positive adjusted operating margins while still growing revenue in the high single digit to low double digit range. The core of the thesis is that the business can become sustainably profitable without collapsing growth.

From a framework perspective, the key levers to watch are:

  • Revenue growth: whether Asana can stabilize or modestly re-accelerate revenue growth from current levels.
  • Gross margin stability: maintaining high-70s to low-80s percent gross margins typical of established SaaS vendors.
  • Operating leverage: slower growth in sales, marketing and R&D expenses relative to revenue.
  • Cash conversion: the degree to which accounting profits translate into operating and free cash flow.
Sources (section – Financial profile): Asana FY2026 earnings release and Form 8-K, Asana FY2025 Form 10-K, and management guidance communicated on recent earnings calls. [1] [2]

Key growth drivers and customer metrics

ARR, net retention and customer mix

For a SaaS business like Asana, the quality of growth matters as much as the absolute level. Three concepts dominate:

  • Annual Recurring Revenue (ARR): Asana’s ARR base has grown in line with reported revenue, with management targeting mid-teens percentage growth over time as macro conditions normalize.
  • Net Revenue Retention (NRR): after a period of triple-digit NRR in earlier years, net retention has moderated into the mid-90s percent range as customers trim seats and rationalize tools. Management has flagged this as an area of focus but still sees healthy expansion in its core customer cohort. [3] [5]
  • Core customers: the number of customers with annualized spend of 5,000 dollars or more reached 25,928 in the latest quarter, up 10 percent year over year. This cohort is important because it tends to have better retention, higher expansion potential and more predictable usage. [3]

Enterprise and vertical expansion

Asana historically started with smaller teams and then expanded within organizations. Over time, the company has moved upmarket into larger enterprises and regulated industries, adding features for security, governance, auditability and compliance. These customers usually have larger average contract values but longer, more complex sales cycles.

AI roadmap and product differentiation

The 2026–2027 product roadmap emphasizes AI-assisted workflows and better alignment between company goals and day-to-day tasks. If customers perceive meaningful productivity gains from these features, they may be willing to consolidate more work on Asana and keep spending stable or growing even in a cautious macro environment. If, however, AI capabilities feel similar across tools, the differentiation will come from price, bundle and ecosystem rather than from the AI label itself.

Sources (section – Growth drivers): Asana FY2026 and FY2025 earnings commentary, business metrics disclosed in IR materials and 8-K, and high-level SaaS industry benchmarks on ARR and NRR dynamics. [1] [3] [5]

Alternative scenarios for 2026–2027

SaaS outcomes are rarely binary. Instead of a single forecast, it is often more useful to think in terms of a spectrum of plausible scenarios. The following bull and bear cases are not price targets, but narrative frames to understand how Asana’s story could evolve over the next 12–24 months.

Bull scenario ⮕

Profitable growth and improving sentiment

  • Revenue growth stabilizes in the high single digits or low double digits, supported by better macro conditions and improved enterprise demand.
  • Net revenue retention gradually trends back toward or above 100 percent as optimization headwinds ease and AI-driven productivity features prove sticky.
  • Asana sustains positive non-GAAP operating margins and moves closer to GAAP breakeven while continuing to invest in product innovation.
  • The market starts to view Asana as a credible “profitable growth” story; valuation multiples expand from current levels, potentially bringing the share price back into the low-to-mid teens over the medium term.
  • Optionality: strategic interest from larger software vendors or financial sponsors looking to consolidate the work management space.

In this scenario, the main drivers are execution on profitability, stabilization of net retention and visible adoption of new features at scale.

Bear scenario ⮕

Persistent headwinds and stalled growth

  • Revenue growth drifts down toward mid single digits as new customer acquisition slows and existing customers keep trimming seats.
  • Net revenue retention remains stuck below 100 percent, making it difficult to deliver both growth and margin expansion.
  • Competitive pressure from bundled productivity suites intensifies, limiting Asana’s ability to raise prices or upsell premium tiers.
  • In order to preserve cash, Asana has to cut deeper into operating expenses, delaying some innovation and potentially affecting the pace of enterprise wins.
  • The stock could remain range-bound or drift lower if investors migrate to faster-growing or more profitable SaaS names, keeping the valuation compressed for longer.

Here the key risks are prolonged macro softness, ongoing net retention pressure, and difficulty clearly differentiating the platform in a crowded market.

Real outcomes are likely to sit between these extremes and will depend on the interaction between macro conditions, competitive responses and Asana’s own execution on both product and go-to-market strategy.

Sources (section – Scenarios): Scenario analysis derived from Asana’s disclosed financials, guidance and common patterns observed in other SaaS transitions from growth to profitability. [1] [2]

Key risk factors

  • Competitive intensity: Asana operates in a space where large platform providers can bundle similar capabilities, pressuring pricing and making differentiation harder.
  • Net retention pressure: If customers continue to reduce seat counts or consolidate tools, net revenue retention could remain below 100 percent, limiting growth.
  • Macro and IT spending: Software budgets are sensitive to economic cycles; a prolonged slowdown could weigh on both new deals and expansions.
  • Execution on profitability: Balancing investment in product and sales with the need to deliver margin expansion carries execution risk.
  • Talent and leadership transitions: Changes in senior leadership or key technical roles could impact strategy and execution if not managed smoothly.
  • Foreign exchange and international expansion: Growing outside the United States introduces currency, regulatory and localization risks.
Sources (section – Risks): Asana Form 10-K “Risk Factors” section and recent earnings commentary highlighting macro, retention and competitive headwinds. [2] [5]

2026–2027 catalyst timeline

  • March 2026 Q4 FY2026 earnings and FY2027 guidance – first comprehensive view of the new profitability phase.
  • June 2026 Q1 FY2027 earnings (quarter ending April 30, 2026) – early read on whether revenue growth and net retention are stabilizing.
  • Second half 2026 Further AI feature rollouts, new enterprise logo wins and potential vertical/geo expansion updates.
  • FY2027 Progress on sustaining positive margins and potential capital allocation announcements (e.g. continued investment vs. balance sheet optimization).
Sources (section – Timeline): Asana investor relations calendar and FY2026 earnings materials outlining the timing of future earnings releases and strategic priorities. [1] [4]

Related official resources

  • Asana Investor Relations – SEC filings, earnings releases and presentations
  • Latest Asana Inc. Form 10-K (interactive data viewer)

These documents provide full financial statements, risk disclosures and management discussion that complement the high-level synthesis in this report.

Disclaimer (EN): This report is intended strictly for educational and informational purposes. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. The information is based on publicly available sources believed to be reliable, including but not limited to filings with securities regulators, official company communications and reputable newswires; however, no guarantee is given as to completeness or accuracy, and figures may be simplified or rounded.

Any forward-looking statements or scenario analyses are inherently uncertain and subject to change without notice. Readers should conduct their own independent research and, where appropriate, consult a qualified financial advisor before making any decision involving Asana Inc. (ASAN) or other securities.

Independent SaaS overview on Asana Inc. (ASAN) – data updated through Q4/FY2026 – no buy/sell recommendation implied.

Executive summary

Asana Inc. (NYSE: ASAN) è una piattaforma cloud di work management che aiuta i team a organizzare, tracciare e gestire progetti e attività. Fondata nel 2008 da Dustin Moskovitz e Justin Rosenstein e quotata dal 2020, oggi è un player SaaS di media capitalizzazione con un valore di mercato nell’ordine di 1,7–1,8 miliardi di dollari a inizio marzo 2026, sulla base di un prezzo azionario intorno a 7,4 dollari e circa 236–238 milioni di azioni in circolazione.

Nell’ultimo trimestre riportato, il quarto trimestre dell’esercizio fiscale 2026 (chiuso il 31 gennaio 2026), Asana ha generato ricavi per 205,6 milioni di dollari, in crescita del 9% su base annua. Su tutto l’esercizio FY2026 i ricavi hanno raggiunto 790,8 milioni di dollari, anche in questo caso in aumento di circa il 9% rispetto al FY2025. In parallelo, il flusso di cassa operativo è stato pari a 27,6 milioni di dollari nel trimestre e circa 90,4 milioni di dollari sull’intero esercizio, un miglioramento molto significativo rispetto ai 14,9 milioni di dollari di flusso di cassa operativo del FY2025. Il margine di free cash flow nel Q4 è salito in area doppia cifra bassa. [1]

Asana registra ancora una perdita netta su base GAAP, ma la traiettoria è chiaramente in miglioramento. La perdita netta GAAP di FY2026 è scesa a 189,0 milioni di dollari dai 255,5 milioni di FY2025, mentre la perdita operativa GAAP si è ridotta da 266,7 a 197,3 milioni di dollari. Su base rettificata, la società è già passata in utile, con margini operativi e utili netti non-GAAP positivi nel FY2026. [1] [2]

Il modello di business è quello tipico SaaS a sottoscrizione: i clienti pagano per utente e per periodo (mensile o annuale), e Asana misura i progressi principalmente tramite Annual Recurring Revenue (ARR), net revenue retention (NRR) e crescita dei “core customers” a maggiore valore. Il management ha recentemente evidenziato che i clienti core con spesa annualizzata pari o superiore a 5.000 dollari sono saliti a 25.928, in crescita del 10% anno su anno, mentre i tassi di retention netta si sono normalizzati nell’area metà-anni 90 percento, in un contesto in cui molte aziende stanno ottimizzando posti e budget software. [3]

È una storia molto diversa rispetto alle small cap biotech con eventi binari. Nel caso di Asana, i driver sono lo scaling ordinato del modello SaaS – acquisizione clienti, espansione all’interno dei clienti esistenti, leva operativa – e il percorso verso una redditività sostenibile. La società compete con altre piattaforme di produttività e project/work management e deve gestire con attenzione il trade-off tra investimenti in crescita (in particolare su AI e funzionalità enterprise) ed espansione dei margini.

I venti contrari recenti includono una domanda software più selettiva in alcuni segmenti, pressioni sulla net retention legate alla razionalizzazione dei tool e una concorrenza intensa da parte delle suite più grandi. Dall’altro lato, Asana oggi ha una struttura di costo più disciplinata, una traiettoria di marginalità in netto miglioramento e una base in crescita di clienti enterprise e mid-market a più alto valore. Il passaggio da “crescita a ogni costo” a “crescita profittevole” è il cuore della narrativa FY2026/FY2027.

Questo report ha finalità esclusivamente informative. Analizza la piattaforma di prodotto, il profilo finanziario, le metriche clienti, il posizionamento competitivo e alcuni scenari bull/bear illustrativi per i prossimi 12–24 mesi, senza fornire alcuna raccomandazione di acquisto o vendita sul titolo.

Fonti (sezione – Executive summary): Form 10-K e 10-Q di Asana Inc., comunicato utili FY2026 e Form 8-K, oltre a dati di mercato da provider istituzionali per prezzo, capitalizzazione e numero di azioni. [1] [2] [4]

Dati chiave (chiusura 3 marzo 2026)

Prezzo azione
$7,44
Range 52 settimane: $6,51 – $19,12
Volatilità moderata per una mid-cap SaaS.
Capitalizzazione
≈ $1,7–1,8B
Imputata da prezzo e numero di azioni diluite (circa 236–238M).
Classificata come società SaaS statunitense di media capitalizzazione.
Consensus analisti
≈ $11
Target medio 12 mesi intorno a 10–12 dollari per azione,
con upside potenziale dai livelli correnti e profilo di rating neutrale/moderato buy.
Ricavi Q4 FY2026
$205,6M
Crescita del 9% anno su anno.
Ricavi FY2026: $790,8M, circa +9% rispetto al FY2025.
Generazione di cassa
$90,4M
Flusso di cassa operativo FY2026 vs $14,9M nel FY2025.
Margine di free cash flow nel Q4 in area doppia cifra bassa.
Clienti core
25.928
Clienti con spesa annua ≥ $5.000, +10% anno su anno.
NRR complessiva in area metà-anni 90; NRR dei clienti core leggermente più alta.
Fonti (sezione – Dati chiave): Comunicato utili FY2026 e Form 8-K, Form 10-K FY2025 per ricavi e cassa, e dati di mercato consolidati da principali provider istituzionali per prezzo, capitalizzazione e target analisti. [1] [2] [4]

Piattaforma di prodotto e posizionamento competitivo

Funzionalità core di work management

La piattaforma Asana è pensata per centralizzare il lavoro su progetti, portafogli e reparti. L’idea di base è permettere ai team di vedere chiaramente chi fa cosa, entro quando, con stato e responsabilità definiti. I pilastri funzionali principali includono:

  • Task e project management: creazione, assegnazione e tracciamento di attività con scadenze, dipendenze, priorità e campi personalizzati.
  • Views e workflow: viste elenco, board, timeline e calendario, oltre ad automazioni per instradare il lavoro tra team diversi.
  • Portfolio e resource management: visibilità su più iniziative, pianificazione della capacità e coordinamento cross-funzione.
  • Reportistica e dashboard: dashboard in tempo reale su stato dei progetti, carico di lavoro e metriche di business.
  • Integrazioni e API: connettori verso tool diffusi (email, chat, CRM, repository di codice, BI) e API per integrazioni custom.
  • Assistenza tramite AI: funzionalità basate su intelligenza artificiale per generare descrizioni di task, riepiloghi e raccomandazioni operative.

Posizionamento nel panorama del work management

Il mercato del work management è affollato, con diversi concorrenti affermati ed emergenti. In modo molto sintetico:

PiattaformaSocietàFocus di mercatoPunti di forza vs AsanaLimiti tipici vs Asana
Monday.comMonday.com Ltd.SMB e mid-marketInterfaccia molto visiva; marketing forte; crescita veloce dei ricaviMinor profondità per gestione portafogli complessi in ambito enterprise
Microsoft 365 / ProjectMicrosoftSuite enterpriseInclusione nelle licenze esistenti; presenza ubiqua nelle grandi aziendeUX più datata in alcuni moduli; maggiore complessità di implementazione
Jira / strumenti correlatiAtlassianTeam software e tecniciProfonda integrazione nei workflow di sviluppo; ecosistema forteCurva di apprendimento ripida; meno intuitiva per utenti non tecnici
SmartsheetSmartsheet Inc.PMO enterprise e team operativiModello tipo foglio di calcolo familiare agli utenti Excel; strumenti di governance robustiUX percepita come meno moderna; configurazione spesso più pesante
AsanaAsana Inc.Mid-market ed enterprise, team di knowledge workUX moderna e intuitiva; forte focus sulla collaborazione; orchestrazione del lavoro e assistenza AINon è l’opzione più economica; fronteggia concorrenza intensa da suite bundle

Il vantaggio competitivo di Asana è più evidente dove le organizzazioni danno priorità all’esperienza utente, alla visibilità cross-funzione e a workflow ben strutturati, più che al solo prezzo o alla massima ampiezza di funzionalità. La società punta a vendere non solo un tool, ma un metodo di lavoro, supportato da programmi di customer success e template di best practice.

Approfondimento – AI e automazione

Una parte importante della tesi di medio termine su Asana riguarda la capacità di usare l’intelligenza artificiale per ridurre attriti nel lavoro di conoscenza. Alcuni esempi di casi d’uso:

  • Generazione di bozze di task e follow-up partendo da note di riunione o email.
  • Riepilogo dello stato di progetto su più attività e assegnatari.
  • Evidenziazione di rischi (task critici in ritardo) e suggerimenti di mitigazione.
  • Raccomandazioni di assegnazione dei task sulla base della capacità disponibile e dei pattern storici di carico lavoro.

La domanda strategica è se i clienti saranno disposti a pagare un premio per queste capacità rispetto a funzionalità “sufficientemente buone” integrate in suite più ampie. L’AI è un’opportunità, ma sta anche diventando rapidamente uno standard in molti strumenti di produttività; per questo esecuzione, differenziazione e profondità di integrazione conteranno almeno quanto l’etichetta “AI” in sé.

Fonti (sezione – Piattaforma e posizionamento): Documentazione prodotto Asana, filing e presentazioni FY2026/FY2025 sul focus di piattaforma e go-to-market, e ricerche di settore sul mercato del work management e del project portfolio management. [2] [3]

Profilo finanziario e percorso verso la redditività

Negli ultimi due esercizi fiscali Asana è passata da un profilo di pura “crescita” a un approccio più bilanciato “crescita e redditività”. I numeri FY2026 rispetto al FY2025 rendono bene questo cambio di fase.

Voce (milioni USD)FY2025FY2026Osservazione chiave
Ricavi totali≈ $723,9M$790,8MCrescita intorno al 9% YoY, in linea con la guidance rivista.
Perdita operativa GAAP$266,7M$197,3MPerdita operativa ridotta di circa 70M di dollari grazie a maggiore disciplina sui costi.
Perdita netta GAAP$255,5M$189,0MPerdita netta ridotta di oltre 60M di dollari anno su anno.
Flusso di cassa operativo$14,9M$90,4MGenerazione di cassa in forte miglioramento; FY2026 è circa 6 volte FY2025.
Margine FCF Q4Bassa singola cifraBassa doppia cifraMargini di free cash flow in chiara fase di espansione, coerenti con la narrativa di redditività.

La guidance FY2027 del management punta a mantenere margini operativi rettificati positivi continuando al tempo stesso a crescere a tassi di high-single digit/low-double digit. Il cuore della tesi è che il business possa diventare stabilmente profittevole senza sacrificare completamente la crescita.

In termini di framework, le leve principali da monitorare sono:

  • Crescita dei ricavi: se Asana riuscirà a stabilizzare o riaccelerare moderatamente la crescita rispetto ai livelli attuali.
  • Stabilità dei margini lordi: mantenere margini lordi tipici delle SaaS mature (alto 70% – basso 80%).
  • Leva operativa: crescita più lenta di spese di vendita/marketing e R&D rispetto ai ricavi.
  • Conversione in cassa: quanto gli utili contabili si traducono effettivamente in flusso di cassa operativo e free cash flow.
Fonti (sezione – Profilo finanziario): Comunicato utili FY2026 e Form 8-K di Asana, Form 10-K FY2025 e indicazioni del management nelle ultime conference call. [1] [2]

Driver di crescita e metriche clienti

ARR, net retention e mix clienti

In un modello SaaS come quello di Asana conta tanto la qualità della crescita quanto il livello assoluto. Tre concetti chiave:

  • Annual Recurring Revenue (ARR): la base ARR di Asana è cresciuta in linea con i ricavi riportati; il management mira nel tempo a tornare verso una crescita percentuale mid-teens man mano che il contesto macro si normalizza.
  • Net Revenue Retention (NRR): dopo un periodo con NRR a tripla cifra, la retention netta si è normalizzata nell’area metà-anni 90 percento, in un contesto in cui molti clienti riducono posti o consolidano tool. È un’area di attenzione, ma il management continua a vedere una buona espansione nel segmento dei clienti core. [3] [5]
  • Clienti core: il numero di clienti con spesa annualizzata pari o superiore a 5.000 dollari ha raggiunto 25.928 nell’ultimo trimestre, in crescita del 10% anno su anno. Questo gruppo tende ad avere retention migliore, maggiore potenziale di espansione e utilizzo più prevedibile. [3]

Espansione enterprise e verticale

Storicamente Asana è entrata spesso dalle squadre più piccole per poi espandersi all’interno dell’organizzazione. Nel tempo la società si è spostata verso l’alto, su clienti enterprise e settori regolamentati, aggiungendo funzionalità per sicurezza, governance, audit e compliance. Questi clienti hanno in genere contratti medi più alti ma cicli di vendita più lunghi e complessi.

Roadmap AI e differenziazione di prodotto

La roadmap 2026–2027 enfatizza workflow supportati da AI e un allineamento migliore tra obiettivi aziendali e attività quotidiane. Se i clienti percepiranno un reale aumento di produttività, potrebbero consolidare più lavoro su Asana e mantenere stabile o in crescita la spesa anche in un contesto macro prudente. Se invece le capacità AI verranno percepite come simili tra i vari strumenti, la differenziazione si giocherà più sul prezzo, sul bundle e sull’ecosistema che sull’etichetta tecnologica.

Fonti (sezione – Driver di crescita): Commenti del management nelle call FY2026/FY2025, metriche operative divulgate nei materiali IR e 8-K, e benchmark di settore sulle dinamiche ARR/NRR per le SaaS. [1] [3] [5]

Scenari alternativi 2026–2027

Gli esiti per una società SaaS raramente sono binari. Più che un’unica previsione puntuale ha senso ragionare su uno spettro di scenari plausibili. I seguenti casi bull e bear non sono target di prezzo, ma cornici narrative per capire come la storia di Asana potrebbe evolvere nei prossimi 12–24 mesi.

Scenario bull ⮕

Crescita profittevole e sentiment in miglioramento

  • La crescita dei ricavi si stabilizza in area high-single digit/low-double digit, sostenuta da un contesto macro meno ostile e da una domanda enterprise più solida.
  • La net revenue retention risale gradualmente verso o oltre il 100%, man mano che le pressioni di ottimizzazione si attenuano e le funzionalità AI dimostrano valore.
  • Asana mantiene margini operativi rettificati positivi e si avvicina al breakeven GAAP continuando a investire in innovazione prodotto.
  • Il mercato comincia a vedere Asana come storia di “crescita profittevole”; i multipli di valutazione si espandono rispetto ai livelli attuali, riportando il titolo in area low-mid teens nel medio termine.
  • Opzionalità: eventuale interesse strategico da parte di grandi vendor software o investitori finanziari interessati a consolidare il segmento work management.

In questo scenario i driver principali sono esecuzione sulla redditività, stabilizzazione della retention e adozione visibile delle nuove funzionalità su larga scala.

Scenario bear ⮕

Venti contrari persistenti e crescita frenata

  • La crescita dei ricavi scende verso la mid single digit per effetto di un rallentamento nelle nuove acquisizioni e di tagli di posti da parte dei clienti esistenti.
  • La net revenue retention resta sotto il 100%, rendendo difficile combinare crescita e miglioramento dei margini.
  • La pressione competitiva da parte delle suite bundle si intensifica, limitando lo spazio di manovra su prezzi e upsell.
  • Per preservare la cassa, Asana è costretta a tagli più profondi sui costi operativi, ritardando parte dell’innovazione e rallentando le vittorie enterprise.
  • Il titolo potrebbe rimanere bloccato in un range o scendere se gli investitori si spostano su nomi SaaS con crescita più veloce o redditività più visibile, mantenendo compressi i multipli per un periodo prolungato.

Qui i rischi centrali sono una debolezza macro persistente, pressioni durature sulla retention e difficoltà nel differenziare con chiarezza la piattaforma in un mercato affollato.

Nella pratica è probabile che l’esito si collochi tra questi estremi e dipenda dall’interazione tra contesto macro, risposte competitive ed esecuzione interna di Asana su prodotto e go-to-market.

Fonti (sezione – Scenari): Analisi di scenario basata sui dati di bilancio e sulla guidance Asana e su pattern osservati in altri percorsi di transizione da “growth” a “growth + profitability” nel settore SaaS. [1] [2]

Principali fattori di rischio

  • Intensità competitiva: Asana opera in un’area in cui i grandi fornitori di suite possono integrare funzionalità simili, comprimendo i prezzi e rendendo più difficile la differenziazione.
  • Pressioni sulla net retention: se i clienti continueranno a ridurre posti o a consolidare tool, la net revenue retention potrebbe rimanere sotto il 100%, limitando la crescita.
  • Macro e spesa IT: i budget software sono sensibili al ciclo economico; un rallentamento prolungato può pesare sia sulle nuove vendite sia sulle espansioni.
  • Esecuzione sulla redditività: bilanciare investimenti in prodotto e vendite con l’espansione dei margini comporta rischi di execution.
  • Talenti e leadership: eventuali transizioni in posizioni chiave di leadership o ruoli tecnici critici possono impattare strategia e execution se non gestite in modo ordinato.
  • Espansione internazionale e cambio: la crescita fuori dagli Stati Uniti introduce rischi valutari, regolatori e di localizzazione.
Fonti (sezione – Rischi): Sezione “Risk Factors” del Form 10-K Asana e commenti del management nelle ultime call su macro, retention e concorrenza. [2] [5]

Timeline catalyst 2026–2027

  • Marzo 2026 Pubblicazione utili Q4 FY2026 e guidance FY2027 – primo quadro completo della nuova fase di redditività.
  • Giugno 2026 Utili Q1 FY2027 (trimestre chiuso il 30 aprile 2026) – primo test su stabilizzazione di crescita ricavi e net retention.
  • Seconda metà 2026 Ulteriori rilasci di funzionalità AI, nuove vittorie enterprise e aggiornamenti su espansione verticale/geografica.
  • FY2027 Progresso verso il mantenimento di margini positivi e possibili annunci sulla strategia di allocazione del capitale (investimenti, ottimizzazione della struttura finanziaria, ecc.).
Fonti (sezione – Timeline): Calendario investor relations Asana e materiali sugli utili FY2026 con indicazioni sul timing dei prossimi trimestri e sulle priorità strategiche. [1] [4]

Risorse ufficiali correlate

  • Asana Investor Relations – filing SEC, comunicati utili e presentazioni
  • Ultimo Form 10-K Asana Inc. (visualizzatore dati interattivo)

Questi documenti contengono bilanci completi, informazioni di rischio e la discussione del management che integra la sintesi di alto livello presentata in questo report.

Disclaimer (IT): Questo report ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria, raccomandazione di investimento né sollecitazione all’acquisto o alla vendita di strumenti finanziari. Le informazioni qui riassunte derivano da fonti pubbliche ritenute affidabili, tra cui filing presso le autorità di vigilanza, comunicazioni ufficiali della società e principali circuiti di newswire, ma non se ne garantisce completezza o accuratezza assoluta; alcuni dati possono essere semplificati o arrotondati.

Eventuali affermazioni prospettiche o scenari illustrativi sono intrinsecamente incerti e soggetti a modifiche senza preavviso. Prima di assumere qualunque decisione su Asana Inc. (ASAN) o altri titoli, il lettore dovrebbe svolgere ricerche autonome e, se del caso, consultare un consulente finanziario abilitato nel proprio ordinamento.

Panoramica indipendente su Asana Inc. (ASAN) – dati aggiornati a Q4/FY2026 – nessuna raccomandazione di acquisto o vendita implicita.

What do you feel about this?

  • Medium Caps Trending

Post navigation

Previous: Ocugen Inc ( $OCGN )
Next: Actelis Networks ( $ASNS ) – Cyber-Hardened Networking For Critical Infrastructure In 2026

Related Stories

Rare Earth
  • Medium Caps Trending

Rare Earth Independence Is Back: $USAR, $CRML and $MP Race to Rebuild the Western Supply Chain

1
USAR May
  • Stocks suggested by members
  • Medium Caps Trending

USA Rare Earth Inc. (Nasdaq: $USAR): from strategic promise to execution pressure

1
  • Weekly Reports
  • Defence
  • Medium Caps Trending
  • Small Caps Trending

WAR US–Israel vs Iran, 2026 Small & mid-cap potential “winners & losers”

4
  • Medium Caps Trending

RGTI Rigetti Computing Inc

0
  • Defence
  • Medium Caps Trending
  • ONDS

ONDS Ondas Inc

1
  • Technology
  • AI
  • BBAI
  • Medium Caps Trending

BBAI BigBear.ai Holdings Inc

5

Trending Now

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC Spy oil inflation 1
  • Editorial

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

22
The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question truce Usa Iran 2
  • Editorial

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

55
Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen cldx 3
  • Reports Biotech

Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

78
Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215 nmra 4
  • Reports Biotech

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

70

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.
✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →
✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.
✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.
```
Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

  • Full reports on individual stocks
  • FDA, catalyst and clinical-trial analysis
  • Daily briefings, watchlists and market themes
  • A free archive updated on a regular basis
Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

  • Report completi su singoli titoli
  • Analisi di catalyst, FDA e trial clinici
  • Daily briefing, watchlist e temi di mercato
  • Un archivio gratuito aggiornato con regolarità
Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Merlintrader Newsletter

Stay ahead of the next catalyst

Get market notes, deep-dive updates and catalyst-focused research directly from Merlintrader.

Educational market content only. No spam. You can unsubscribe anytime.
Terms, privacy and disclaimer
DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Scanner for active traders
ChartsWatcher logo

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform
Medved Trader logo

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

Donate via PayPal

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Buy Me a Coffee

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

  • Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
  • ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
  • Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
  • Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
  • Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
  • Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Terms and Conditions
Cookie Policy
Privacy Policy
Merlintrader is a personal blog curated by Horacio F. Greco. Contact: info@merlintrader.com. No professional financial advice.
Do Not Sell or Share My Personal Information